NOVELTY – The pharmacological use of neolignans and their derivatives and analogs comprises application of micro- and nanoparticles of lactic and glycollic acids (D,L-PLGA) containing neolignans. Also claimed is a process making the products. CLAIMED PROCESS – The process comprises emulsification and evaporation of solvent with a controlled pharmaceutical release system for treatment of e.g. human and cattle tuberculosis and HIV. EMBODIMENT – Administration is oral nasal, subcutaneous and e.g. intramuscular with or without other formulations. USE – In physical chemistry.

Main Application Field

A96 (Medical, dental, veterinary, cosmetic.); B05 (Other organics – aromatics, aliphatic, organo-metallics, compounds whose substituents vary such that they would be classified in several of B01 – B05.); B07 (General – tablets, dispensers, catheters (excluding drainage and angioplasty), encapsulation etc, but not systems for administration of blood or saline or IV feeding etc.)

INVENTORS:

SILVA CELIO LOPES
SOUZA ANA OLIVIA DE
BARATA LAURO EUCLIDES SOARES
BENTLEY MARIA VITORIA LOPES BA
MINARINI PAULO ROBERTO REGAZI

36_NEOLIGNANAS

Patent number: BR200600679-A

PATENT STATUS:

For information contact Inova Unicamp

FOR ADDITIONAL INFORMATION:

parcerias@inova.unicamp.br

+55 (19) 3521-5207 / 2607

This technology profile has been automatically generated.